Transmedics Group Share Price (NASDAQ: TMDX)

$118.79

▲

-3.09

(-2.54%)

Live

Last updated on August 21, 2025 at 10:42 PM IST

$₹

Check the interactive Transmedics Group Stock chart to analyse performance

Transmedics Group stock performance

as on August 21, 2025 at 10:42 PM IST

Today's Low:$118.00
Today's High:$120.21
$118.79
0.67%
Downside
Day's Volatility :1.84%
Upside
1.18%
52 Weeks Low:$55.00
52 Weeks High:$177.37
$118.79
53.7%
Downside
52 Weeks Volatility :68.99%
Upside
33.03%

Transmedics Group Stock Returns

Period	Transmedics Group Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-1.19%	4.5%	0.0%
6 Months	61.52%	-6.1%	0.0%
1 Year	-29.53%	-11.1%	0.0%
3 Years	158.97%	3.4%	-9.6%

Transmedics Group Inc Key Stats

Check Transmedics Group key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$121.88
Open	$122.26
Today's High	$120.21
Today's Low	$117.5
Market Capitalization	$4.2B
Today's Volume	$834.2K
52 Week High	$177.37
52 Week Low	$55.0
Revenue TTM	$531.3M
EBITDA	$100.3M
Earnings Per Share (EPS)	$1.99
PE Ratio	61.65
Profit Margin	13.49%
Quarterly Earnings Growth YOY	1.63%
Return On Equity TTM	28.21%

Stock Returns calculator for Transmedics Group Stock including INR - Dollar returns

The Transmedics Group stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Transmedics Group investment value today

Current value as on today

₹72,612

Returns

₹27,388

(-27.39%)

Returns from Transmedics Group Stock

₹31,315 (-31.32%)

Dollar Returns*

₹3,927 (+3.93%)

Indian investors sentiment towards Transmedics Group Stock

1.04%

Period: Jul 21, 2025 to Aug 20, 2025. Change in 30 Days versus previous period

Investment in Transmedics Group Shares from India has grown by 1.04% over the past 30 days, indicating increased transactional activity.

-30%

Period: Jul 21, 2025 to Aug 20, 2025. Change in 30 Days versus previous period

Search interest for Transmedics Group Stock from India on INDmoney has decreased by -30% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Transmedics Group Inc

Name
Holdings %
Name
Holdings %
BlackRock Inc
15.39%
FMR Inc
14.66%
Vanguard Group Inc
10.55%
State Street Corp
3.83%
Fidelity International Ltd
3.60%
Macquarie Group Ltd
3.27%

Analyst Recommendation on Transmedics Group Stock

Rating

Trend

Buy

84%Buy

15%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Transmedics Group(by analysts ranked 0 to 5 stars)

Transmedics Group Share Price Target

What analysts predicted

Upside of 19.78%

Target:

$142.29

Current:

$118.79

Transmedics Group share price target is $142.29, a slight Upside of 19.78% compared to current price of $118.79 as per analysts' prediction.

Transmedics Group Stock Insights

Price Movement
In the last 1 month, TMDX stock has moved up by 17.6%
Increasing Revenue
Revenue is up for the last 4 quarters, 108.76M → 157.37M (in $), with an average increase of 11.5% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, 4.21M → 34.90M (in $), with an average increase of 46.1% per quarter
TMDX vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 34.6% return, outperforming this stock by 64.1%
Price to Sales
ForTMDX every $1 of sales, investors are willing to pay $7.7, whereas for Boston Scientific Corp., the investors are paying $8.5 for every $1 of sales.

Transmedics Group Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$23.6M	↑ 81.33%
Net Income	$-33.5M	↑ 41.21%
Net Profit Margin	-142.12%	↑ 40.38%

	FY20	Y/Y Change
Revenue	$25.6M	↑ 8.62%
Net Income	$-28.7M	↓ 14.31%
Net Profit Margin	-112.13%	↑ 29.99%

	FY21	Y/Y Change
Revenue	$30.3M	↑ 18.03%
Net Income	$-44.2M	↑ 53.8%
Net Profit Margin	-146.11%	↓ 33.98%

	FY22	Y/Y Change
Revenue	$93.5M	↑ 208.83%
Net Income	$-36.2M	↓ 18.06%
Net Profit Margin	-38.77%	↑ 107.34%

	FY23	Y/Y Change
Revenue	$241.6M	↑ 158.53%
Net Income	$-25.0M	↓ 30.92%
Net Profit Margin	-10.36%	↑ 28.41%

	FY24	Y/Y Change
Revenue	$441.5M	↑ 82.74%
Net Income	$35.5M	↓ 241.7%
Net Profit Margin	8.03%	↑ 18.39%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$96.9M	↑ 19.31%
Net Income	$12.2M	↑ 202.58%
Net Profit Margin	12.59%	↑ 7.62%

	Q2 FY24	Q/Q Change
Revenue	$114.3M	↑ 18.02%
Net Income	$12.2M	↓ 0.02%
Net Profit Margin	10.67%	↓ 1.92%

	Q3 FY24	Q/Q Change
Revenue	$108.8M	↓ 4.85%
Net Income	$4.2M	↓ 65.43%
Net Profit Margin	3.88%	↓ 6.79%

	Q4 FY24	Q/Q Change
Revenue	$121.6M	↑ 11.83%
Net Income	$6.9M	↑ 62.64%
Net Profit Margin	5.64%	↑ 1.76%

	Q1 FY25	Q/Q Change
Revenue	$143.5M	↑ 18.02%
Net Income	$25.7M	↑ 274.54%
Net Profit Margin	17.89%	↑ 12.25%

	Q2 FY25	Q/Q Change
Revenue	$157.4M	↑ 9.64%
Net Income	$34.9M	↑ 35.92%
Net Profit Margin	22.18%	↑ 4.29%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$13.9M	↑ 141.77%

	FY20	Y/Y Change
Profit	$16.6M	↑ 20.0%

	FY21	Y/Y Change
Profit	$21.2M	↑ 27.2%

	FY22	Y/Y Change
Profit	$65.3M	↑ 208.48%

	FY23	Y/Y Change
Profit	$154.1M	↑ 136.08%

	FY24	Y/Y Change
Profit	$262.1M	↑ 70.08%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$59.9M	↑ 24.91%

	Q2 FY24	Q/Q Change
Profit	$69.2M	↑ 15.53%

	Q3 FY24	Q/Q Change
Profit	$60.8M	↓ 12.02%

	Q4 FY24	Q/Q Change
Profit	$72.0M	↑ 18.35%

	Q1 FY25	Q/Q Change
Profit	$88.2M	↑ 22.52%

	Q2 FY25	Q/Q Change
Profit	$96.6M	↑ 9.48%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-32.3M	↑ 24.25%
Investing Cash Flow	$-60.5M	↓ 591.6%
Financing Cash Flow	$92.7M	↑ 320.25%

	FY20	Y/Y Change
Operating Cash Flow	$-30.3M	↓ 6.26%
Investing Cash Flow	$-41.6M	↓ 31.24%
Financing Cash Flow	$75.5M	↓ 18.52%

	FY21	Y/Y Change
Operating Cash Flow	$-28.9M	↓ 4.63%
Investing Cash Flow	$29.3M	↓ 170.36%
Financing Cash Flow	$1.4M	↓ 98.16%

	FY22	Y/Y Change
Operating Cash Flow	$-45.8M	↑ 58.73%
Investing Cash Flow	$54.5M	↑ 86.26%
Financing Cash Flow	$167.9M	↑ 11955.06%

	FY23	Y/Y Change
Operating Cash Flow	$-13.0M	↓ 71.57%
Investing Cash Flow	$-194.0M	↓ 455.79%
Financing Cash Flow	$400.4M	↑ 138.45%

	FY24	Y/Y Change
Operating Cash Flow	$48.8M	↓ 474.6%
Investing Cash Flow	$-129.3M	↓ 33.33%
Financing Cash Flow	$22.9M	↓ 94.29%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-3.4M	↓ 141.37%
Investing Cash Flow	$-44.2M	↑ 5.63%
Financing Cash Flow	$3.2M	↑ 244.7%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$25.7M	↓ 848.7%
Investing Cash Flow	$-23.8M	↓ 46.2%
Financing Cash Flow	$10.6M	↑ 234.1%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$6.9M	↓ 73.34%
Investing Cash Flow	$-47.8M	↑ 100.99%
Financing Cash Flow	$7.9M	↓ 26.12%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$19.7M	↑ 186.76%
Investing Cash Flow	$-13.6M	↓ 71.51%
Financing Cash Flow	$1.2M	↓ 84.91%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-2.9M	↓ 114.52%
Investing Cash Flow	$-27.0M	↑ 98.72%
Financing Cash Flow	$3.0M	↑ 155.31%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$91.6M	↓ 3308.72%
Investing Cash Flow	$-9.1M	↓ 66.44%
Financing Cash Flow	$7.1M	↑ 134.11%

Transmedics Group Technicals Summary

Sell

Neutral

Buy

Transmedics Group is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Transmedics Group Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Transmedics Group Inc	15.41%	61.52%	-29.53%	158.97%	580.84%
Medtronic Plc	1.69%	5.98%	6.47%	0.12%	-6.92%
Edwards Lifesciences Corp.	6.66%	8.93%	16.11%	-15.11%	3.39%
Boston Scientific Corp.	2.79%	0.65%	34.55%	157.0%	172.32%
Stryker Corporation	-0.84%	1.41%	13.47%	84.53%	107.65%
Abbott Laboratories	5.35%	-0.53%	18.92%	23.28%	30.64%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Transmedics Group Inc	61.65	61.65	NA	2.25	0.28	0.06	NA	9.35
Medtronic Plc	25.51	25.51	2.16	5.46	0.1	0.04	0.03	37.46
Edwards Lifesciences Corp.	34.05	34.05	4.72	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	61.76	61.76	1.79	2.98	0.12	0.05	NA	15.14
Stryker Corporation	51.58	51.58	2.17	13.49	0.14	0.08	0.01	55.43
Abbott Laboratories	16.47	16.47	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Transmedics Group Inc	Buy	$4.2B	580.84%	61.65	13.49%
Medtronic Plc	Buy	$118.0B	-6.92%	25.51	13.9%
Edwards Lifesciences Corp.	Buy	$47.8B	3.39%	34.05	72.96%
Boston Scientific Corp.	Buy	$153.7B	172.32%	61.76	13.55%
Stryker Corporation	Buy	$149.1B	107.65%	51.58	12.25%
Abbott Laboratories	Buy	$228.4B	30.64%	16.47	32.43%

About Transmedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Organization	Transmedics Group
Employees	728
CEO	Dr. Waleed H. Hassanein M.D.
Industry	Medical Specialties

Key Management of Transmedics Group Inc

Name	Title
Dr. Waleed H. Hassanein M.D.	Founder, President, CEO & Director
Mr. Gerardo Hernandez	CFO & Treasurer
Mr. Nicholas Corcoran	Senior Vice President of Supply Chain & Operations
Mr. Anil Ranganath	Senior VP, General Counsel & Corporate Secretary
Dr. Tamer I. Khayal M.D.	Chief Commercial Officer
Ms. Miriam C. Provost Ph.D.	Vice President of Global Regulatory Affairs

Important FAQs about investing in TMDX Stock from India :

What is Transmedics Group share price today?

Transmedics Group share price today is $118.79 as on August 21, 2025 at 10:42 PM IST. Transmedics Group share today touched a day high of $120.21 and a low of $118.00.

What is the 52 week high and 52 week low for Transmedics Group share?

Transmedics Group share touched a 52 week high of $177.37 and a 52 week low of $55.00. Transmedics Group stock price today i.e. August 21, 2025 at 10:42 PM IST is trending at $118.79, lower by 33.03% versus the 52 week high.

How to invest in Transmedics Group Stock (TMDX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Transmedics Group on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Transmedics Group Shares that will get you 0.0126 shares as per Transmedics Group share price of $118.79 per share as on August 21, 2025 at 10:42 PM IST.

What is the minimum amount required to buy Transmedics Group Stock (TMDX) from India?

Indian investors can start investing in Transmedics Group (TMDX) shares with as little as ₹87.2 or $1 (as of August 21, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹872.00 in Transmedics Group stock (as per the Rupee-Dollar exchange rate as on August 21, 2025). Based on Transmedics Group share’s latest price of $118.79 as on August 21, 2025 at 10:42 PM IST, you will get 0.0842 shares of Transmedics Group. Learn more about fractional shares .

What are the returns that Transmedics Group has given to Indian investors in the last 5 years?

Transmedics Group stock has given 580.84% share price returns and 17.57% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?